Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Northwestern Memorial Hospital studying arthritis drug’s potential in fighting cancer

01.07.2003


A research study under way at Northwestern Memorial Hospital is trying to find out if the popular anti-inflammatory drug Celebrex might do more than ease arthritis pain. Researchers at Northwestern Memorial are enrolling patients with early stage head and neck cancers or non-small cell lung cancers in a research study to see if Celebrex reduces the return of old tumors or the chance of getting a new cancer when taken after surgery or radiation treatments.



The double-blind, randomized study will enroll about 120 patients at Northwestern Memorial, the primary teaching hospital of Northwestern University’s Feinberg School of Medicine. Celebrex belongs to a class of drugs called COX-2 inhibitors that block the production of an enzyme called cyclooxygenese–2 or simply COX-2. COX-2 triggers pain and inflammation in arthritis sufferers and may also fuel the growth of cancer.

"COX-2 inhibitors have emerged in recent years as a promising anticancer therapy. Many cancers have high levels of COX-2," explains Athanassios Argiris, M.D., an oncologist at Northwestern Memorial Hospital. Dr. Argiris, who coordinates the clinical research in lung as well as head and neck cancer at the Robert H. Lurie Comprehensive Cancer Center, is the principal investigator of the research study, which is also expected to open in other major institutions in the U.S. in the coming months. COX-2 may promote the growth of new blood vessels that nourish the cancer tumors. "Taking Celebrex may starve the tumor of nutrients in a process called anti-angiogenesis," he says. "It also appears to promote self-destruction of cancer cells."


Based on successful clinical trials, Celebrex has been FDA-approved to treat those with a genetic syndrome, called familial adenomatous polyposis (FAP), a disorder that greatly increases the risk of colon cancer. Researchers expect that Celebrex may have similar positive effects for cancer treatment and prevention of other cancers.

Several clinical trials are under way to look at COX-2 inhibitors and their ability to prevent and treat a variety of cancers. "As far as I know, this is the only current study of its kind for head and neck cancer," says Dr. Argiris. "I’m expecting that COX-2 inhibitors, such as Celebrex, may slow tumor growth or shrink existing tumors in people with head and neck and lung cancers. Moreover, COX-2 inhibitors may act early in the cancer process and prevent formation of new tumors," says Dr. Argiris. "Celebrex is considered to be safer on the stomach than aspirin, so the reduced gastrointestinal side effects make this an especially exciting therapy," says Dr. Argiris.


###
For more information on this study, call Northwestern Memorial’s physician referral line at 877-926-4664.

About Northwestern Memorial Hospital

Northwestern Memorial Hospital (NMH) is one of the country’s premier academic medical centers and is the primary teaching hospital of Northwestern University’s Feinberg School of Medicine. Northwestern Memorial and its Prentice Women’s Hospital have 720 beds and more than 1,200 affiliated physicians and 5,000 employees. Providing care in a state-of-the-art facility, the hospital is recognized for its outstanding clinical and surgical advancements in such areas as cardiothoracic and vascular care, gastroenterology, neurology and neurosurgery, oncology, organ and bone marrow transplantation, and women’s health.

Northwestern Memorial was ranked as the nation’s 5th best hospital by the 2002 Consumer Checkbook survey of the nation’s physicians and is listed in the majority of specialties in this year’s US News & World Report’s issue of "America’s Best Hospitals." NMH is also cited as one of the "100 Best Companies for Working Mothers" by Working Mother magazine and has been chosen by Chicagoans year after year as their "most preferred hospital" in National Research Corporation’s annual survey.

Amanda Widtfeldt | EurekAlert!
Further information:
http://www.nmh.org/

More articles from Health and Medicine:

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

nachricht Alzheimer’s: Cellular Mechanism Provides Explanation Model for Declining Memory Performance
21.09.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Chains of nanogold – forged with atomic precision

23.09.2016 | Life Sciences

New leukemia treatment offers hope

23.09.2016 | Health and Medicine

Self-assembled nanostructures hit their target

23.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>